Chief Minister A. Revanth Reddy will inaugurate BioAsia 2026, the next edition of Asia’s premier life sciences and health technology forum, on February 17 in Hyderabad.
The 23rd edition of the annual series, themed “TechBio Unleashed: AI, Automation and the Biology Revolution,” will bring together policymakers, the world’s top biotech and pharmaceutical leaders, including Amgen, Sanofi and Eli Lilly, and regulators.
The two-day event will be attended by Union Ministers Piyush Goyal and Ashwini Vaishnaw and Telangana IT and Industries Minister D. Sridhar Babu, along with some of the most influential voices from biotechnology, pharma, healthcare, medicine, artificial intelligence and advanced manufacturing, organizers said on Thursday.
Bruce L. Levine, Professor of Cancer Gene Therapy, University of Pennsylvania; Howard Y. Chang, Chief Scientific Officer and SVP Global Research of Amgen, Stefan Miltenyi, Founder and President of Miltenyi Biotec & Madeliene Roach, EVP – Global Business Services of Sanofi will deliver keynote speeches. Ajay Kumar Sood, Chief Scientific Adviser to the Government of India, and Rajeev Singh Raghuvanshi, Drug Controller General of India, are also scheduled to address the rally.
Google DeepMind Vice President of Science Pushmeet Kohli will bring insights from the frontiers of artificial intelligence – highlighting how fundamental models, breakthroughs in protein science, and advanced reinforcement learning are accelerating discoveries across biology and medicine.
Leadership team members from Dr.Reddy’s Laboratories, Zydus, Biocon and Cipla will participate in a general conclave on “Future of Pharma and Biotechnology”.
Executives from Novartis, Roche, Novo Nordisk, Medtronic, Merck, BMS, Takeda, Lonza, Charles River Laboratories, Ginkgo Bioworks and AstraZeneca will address panel discussions on a variety of topics, including GCCs as innovation engines and next-generation biologics, cell and gene therapies, mRNA and radiopharmaceuticals.
BioAsia will explore how artificial intelligence (AI), advanced biology and smart manufacturing are converging to fundamentally change the way therapies are discovered, developed and delivered around the world. As biology becomes increasingly programmable and artificial intelligence rapidly compresses R&D and manufacturing timelines, the TechBio paradigm is shifting from experimentation to execution. BioAsia 2026 will serve as a platform for meeting leaders who are actively shaping AI-driven discovery platforms, next-generation biologics and digitally integrated operating models across global healthcare.
A dedicated session on Telangana Rising Vision 2047 will outline the state’s plan for growth based on innovation across advanced modalities, R&D with artificial intelligence and next-generation bio-manufacturing, the organizers said.
Published – 05 Feb 2026 20:35 IST
